Trial · NCT07903415
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
NCT07903415, Phase 1, Recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. Trials, record NCT07903415. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903415
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- NCT number
- NCT07903415
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 280 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- PF-08098488
- First posted
- 2026-10-29
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Adverse Events (AEs) | Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first) | Number of participants with AEs, characterized by type, frequency, severity, seriousness, and relationship to study intervention during the AE evaluation period. |
| Primary | Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM) | From first dose through completion of Part 1, an average of 1 year | |
| Primary | Part 2: Recommended Monotherapy Dose for Further Development | From first dose through completion of Part 2, an average of 2 years | |
| Secondary | Objective Response Rate (ORR) | From baseline until first documented disease progression, death, or start of new anticancer therapy, whichever occurs first, up to approximately 3 years | Percentage of participants with a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator. |
| Secondary | Duration of Response (DOR) | From the date of first objective response until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years | Time in weeks/months from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. |
| Secondary | Progression Free Survival (PFS) | From first dose until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years | PFS as defined per RECIST 1.1. |
| Secondary | Overall Survival (OS) | From first dose until death due to any cause, up to approximately 3 years | Time in weeks from the start of study treatment to date of death due to any cause. |
| Secondary | Maximum Observed Serum Concentration (Cmax) | From first dose through End of Treatment (EOT), up to approximately 3 years | |
| Secondary | Area under the concentration-time curve (AUC) | From first dose through End of Treatment (EOT), up to approximately 3 years | |
| Secondary | Time to Maximum Observed Serum Concentration (Tmax) | From first dose through End of Treatment (EOT), up to approximately 3 years |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903415
GET https://conductscience.org/api/trials/v1/NCT07903415/registered